Washington Trust Advisors, Inc. Centessa Pharmaceuticals PLC Transaction History
Washington Trust Advisors, Inc.
- $1.09 Billion
- Q1 2025
A detailed history of Washington Trust Advisors, Inc. transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Washington Trust Advisors, Inc. holds 184 shares of CNTA stock, worth $2,537. This represents 0.0% of its overall portfolio holdings.
Number of Shares
184Holding current value
$2,537% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CNTA
# of Institutions
118Shares Held
120MCall Options Held
7KPut Options Held
220K-
Medicxi Ventures Management (Jersey) LTD20MShares$275 Million75.25% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$137 Million99.89% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$134 Million5.81% of portfolio
-
Perceptive Advisors LLC New York, NY6.35MShares$87.6 Million3.55% of portfolio
-
First Light Asset Management, LLC Edina, MN5.81MShares$80.1 Million9.51% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.3B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...